KLRS

Business Context and Reporting Period

This summary covers the Annual Report on Form 10-K for AlloVir, Inc. (trading symbol: ALVR) for the fiscal year ended December 31, 2024. Although the request metadata mentions "Kalaris Therapeutics, Inc.," the filing is for AlloVir, which is currently in the process of merging with Kalaris. Upon closing, the combined entity is expected to be named Kalaris Therapeutics, Inc. and trade under the ticker "KLRS."

AlloVir is a clinical-stage biopharmaceutical company that discontinued its three Phase 3 registrational trials for its lead product candidate, posoleucel, in December 2023 following futility analyses. Consequently, the company has ceased clinical development of all product candidates and is focused on maximizing shareholder value through a proposed merger with Kalaris or, alternatively, liquidation.

Key Financial Metrics

Note: The company has no revenue and has incurred net losses since inception. The significant reduction in 2024 operating expenses is due to the discontinuation of clinical trials and a workforce reduction of approximately 95%.

Material Changes vs. Prior Period

• Discontinuation of Clinical Trials: In December 2023, AlloVir discontinued three Phase 3 trials for posoleucel (prevention of multi-virus infections, treatment of hemorrhagic cystitis, and treatment of adenovirus infection) due to futility. Development of all other candidates (ALVR106, ALVR107) was also halted.
• Workforce Reduction: The company implemented a restructuring plan in early 2024, reducing its workforce by approximately 95%. This resulted in $10.2 million in restructuring costs (severance and termination benefits) in 2024, compared to none in 2023.
• Impairment Costs: In 2023, the company recorded $18.6 million in impairment costs related to operating leases and other assets. There were no impairment costs in 2024 as leases were terminated and paid off.
• Reverse Stock Split: On January 15, 2025, a 1-for-23 reverse stock split was effected. All historical share and per-share data in the filing have been adjusted to reflect this split.
• Executive Leadership Change: Diana Brainard resigned as CEO in December 2024. Vikas Sinha was appointed CEO, President, and CFO effective December 19, 2024.

Guidance, Outlook, and Risks

Merger with Kalaris Therapeutics

On November 7, 2024, AlloVir entered into a definitive merger agreement with Kalaris Therapeutics, Inc. Key terms include:

• Structure: Kalaris will become a wholly-owned subsidiary of AlloVir. The combined company will be named Kalaris Therapeutics, Inc. and trade under "KLRS."
• Ownership: Pre-merger Kalaris stockholders are expected to own approximately 75.34% of the combined company, while pre-merger AlloVir stockholders will own approximately 24.66%.
• Valuation: The exchange ratio assumes an AlloVir valuation of $116.0 million (subject to cash adjustments) and a Kalaris valuation of $347.0 million.
• Closing Conditions: Includes stockholder approval (AlloVir special meeting scheduled for March 12, 2025) and a minimum net cash condition of $95.0 million at closing.
• Termination Fees: If terminated under specified circumstances, AlloVir could pay Kalaris $3.48 million, or Kalaris could pay AlloVir $10.41 million.

Going Concern and Liquidity

Management has concluded there is substantial doubt regarding the company's ability to continue as a going concern for more than twelve months following the issuance of the financial statements, primarily due to the discontinuation of all clinical trials and the reliance on the merger for future viability. However, the company believes its cash balance of $118.3 million is sufficient to fund operations for at least twelve months.

Key Risks

• Merger Failure: If the merger is not completed, AlloVir may pursue liquidation. The amount of cash available for distribution to stockholders would depend on the timing of liquidation and the amount reserved for liabilities.
• Legal Proceedings: A securities class action lawsuit (Zerbato v. AlloVir, Inc.) was filed in January 2024 regarding the Phase 3 trial discontinuation. The parties reached a settlement in principle in March 2025, subject to court approval.
• Intellectual Property: The company depends on licenses from Baylor College of Medicine (BCM). Termination of these licenses could harm the business.

Important Facts for Investor Verification

• Merger Approval Status: Verify the outcome of the special stockholder meeting scheduled for March 12, 2025, to confirm if the merger with Kalaris will proceed.
• Cash Position at Closing: Confirm that AlloVir's net cash at the time of the merger closing meets the minimum threshold of $95.0 million required by the merger agreement.
• Settlement of Litigation: Monitor the final court approval of the settlement in the Zerbato securities class action lawsuit to understand potential cash outflows.
• Bridge Financing: Verify the status of the "Additional Permitted Bridge Financing" ($7.5 million funded by AlloVir to Kalaris in January 2025) and whether the second tranche will be funded.
• Liquidation Scenario: If the merger fails, review the company's plan for asset liquidation and the estimated timeline for potential cash distributions to shareholders.